JP2014094963A - アミノレブリン酸およびその誘導体の使用 - Google Patents
アミノレブリン酸およびその誘導体の使用 Download PDFInfo
- Publication number
- JP2014094963A JP2014094963A JP2014009382A JP2014009382A JP2014094963A JP 2014094963 A JP2014094963 A JP 2014094963A JP 2014009382 A JP2014009382 A JP 2014009382A JP 2014009382 A JP2014009382 A JP 2014009382A JP 2014094963 A JP2014094963 A JP 2014094963A
- Authority
- JP
- Japan
- Prior art keywords
- pdt
- ala
- composition
- treatment
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
Abstract
【解決手段】該PDTは(a)、(b)を含み:(a)該組成物を該動物に投与すること;及び(b)該5−ALAヘキシルエステルを光活性化すること、そして(i)と(iii)とを組み合わせて用いることによって、該PDTによる副作用が抑えられるか又は和らげられる:(i)該組成物が、0.5〜6重量%の濃度で該5−ALAヘキシルエステルを含むこと、(iii)該光活性化が、フルエンス率が5〜40mW/cm2の光源を用いて行われること。
【選択図】なし
Description
(a)該光増感剤を含む組成物を該動物に投与すること;および
(b)該光増感剤を光活性化すること、
(i)〜(iv)のうち1以上を用いることによって、該PDTの副作用(例えば、痛みおよび/または紅斑)が抑えられるかまたは和らげられる:
(i)該組成物が、10重量%未満(例えば、0.5〜8重量%)の濃度で該光増感剤を含むこと、
(ii)該組成物が、該光活性化をする前2時間未満(例えば、30〜90分間)に投与されること、
(iii)該光活性化が、フルエンス率が50mW/cm2未満(例えば、5〜40mW/cm2)の光源を用いて行われること、
(iv)該光活性化が、太陽光により実施されること。
(a)先に定義したような光増感剤を含む組成物を動物に投与すること;および
(b)該光増感剤を光活性化すること、
(i)〜(iv)のうち1以上を用いることによって、該PDTの副作用(例えば、痛みおよび/または紅斑)が抑えられるかまたは和らげられる:
(i)該組成物が、10重量%未満(例えば、0.5〜8重量%)の濃度で該光増感剤を含むこと、
(ii)該組成物が、該光活性化をする前2時間未満(例えば、30〜90分間)に投与されること、
(iii)該光活性化が、フルエンス率が50mW/cm2未満(例えば、5〜40mW/cm2)の光源を用いて行われること、
(iv)該光活性化が、太陽光により実施されること。
好ましい置換されたアルキルR1基は、1以上のオキソ基を有する基、1,2または3(好ましくは2または3)のオキソ基によって置換された直鎖状C4-12のアルキル基(例えば、C8-10アルキル基)である。このような基として、例えば、3,6−ジオキサ−1−オクチル基および3,6,9−トリオキサ−1−デシル基が挙げられる。
ヘマトポルフィリン誘導体(HpD);
フォトフリン[Photofrin](登録商標)(クアドラ ロジック テクノロジーズ社,バンクーバー,カナダ)やヘマトポルフィリンIX(HpIX)などのヘマトポルフィリン;
フォトサン[Photosan]III(シーホフ ラボラトリアム社,シーホフ,ヴェッセルブレーネルコーフ,ドイツ);
テトラ(m−ヒドロキシフェニル)クロリン(m−THPC)およびバクテリオクロリン(スコティア製薬会社,サリー州,イギリス)、モノ−L−アスパラチルクロリンe6(NPe6)(日本石油化学会社,カリフォルニア州,アメリカ)、クロリンe6(ポルフィリン プロダクト社)、ベンゾポルフィリン(クアドラ ロジック テクノロジーズ社,バンクーバー,カナダ)(例えば、benzoporphyrin derivative monoacid ring A、BPD−MA)、プルプリン[purpurine](PDT製薬会社,カリフォルニア州,アメリカ)(例えば、スズ−エチルエチオプルプリン[tin-ethyl etiopurpurin]、SnET2)などのクロリン;
フタロシアニン(例えば、亜鉛−(クアドラ ロジック テクノロジーズ社,バンクーバー,カナダ)、いくらかのアルミニウム−またはシリコンフタロシアニン。これらはスルホン酸化されていてもよく、特にアルミニウムフタロシアニンジ−スルホン酸(AlPcS2a)またはアルミニウムフタロシアニンテトラ−スルホン酸(AlPcS4)などのスルホン酸化フタロシアニン);
ポルフィセン;
ヒポクレリリン[hypocrellin];
プロトポルフィリンIX(PpIX);
ヘマトポルフィリンジ−エステル;
ウロポルフィリン;
コプロポルフィリン;
ジュウテロポルフィリン;
ポリヘマトポルフィリン(PHP)、ならびにそれらの前駆体、誘導体;および
テトラサイクリン(例えば、トピサイクリン[Topicycline](登録商標)、シャイアー社[Shire])。
(a)先に定義した組成物(例えば、20重量%未満の濃度(例 10重量%の濃度)の5−ALAまたは5−ALAの誘導体である光増感剤を含む組成物)を有する容器、および
(b)先に定義した該PDTを実施するための使用説明書。
(I)上記光増感剤の濃度は、少なくとも15重量%(例えば、16重量%)であり、
(II)該光増感剤は、光活性化する少なくとも3時間前(例えば、3時間前)に投与され;そして
(III)光活性化は、フルエンス率が少なくとも60mW/cm2(例えば、約70mW/cm2)の光源により実施される。
顔面尋常性座瘡(顔面の少なくとも片側に、丘疹膿疱性座瘡および少なくとも15の炎症性座瘡病変)を有する男性23名および女性20名(18歳以上)に対して、第2相臨床研究を実施した。
照射中のフルエンス率を減少させることによる効果を評価するために研究を行なった。
太陽光による照射がPDTランプを用いた場合と同様に有効であることを実証するために研究を行なった。
Claims (6)
- 膣腔、子宮頸部または子宮の内層のウイルス感染の治療のための動物に対する光線力学的療法(PDT)に用いる組成物の製造における、5−アミノレブリン酸(5−ALA)ヘキシルエステルまたはその薬剤として使用し得る塩の使用であって、該PDTは(a)、(b)を含み:
(a)該組成物を該動物に投与すること;および
(b)該5−ALAヘキシルエステルを光活性化すること、
(i)と(iii)とを組み合わせて用いることによって、該PDTによる副作用を抑えるかあるいは少なくする:
(i)該組成物が、0.5〜6重量%の濃度で該5−ALAヘキシルエステルを含むこと、
(iii)該光活性化が、フルエンス率が5〜40mW/cm2の光源を用いて行われることを特徴とする使用。 - 上記PDTによる副作用が、痛みおよび/または紅斑である請求項1に記載の使用。
- 上記組成物が5−ALAヘキシルエステルの塩酸塩を含む、請求項1または2に記載の使用。
- 上記光活性化が400〜700nmの波長範囲の光で行われる請求項1〜3のいずれか一項に記載の使用。
- 上記PDTが40〜200J/cm2の光線量で行われる請求項1〜4のいずれかに記載の使用。
- 上記PDTが100J/cm2の光線量で行われる請求項5に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700580.4 | 2007-01-11 | ||
GBGB0700580.4A GB0700580D0 (en) | 2007-01-11 | 2007-01-11 | Use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545231A Division JP5814508B2 (ja) | 2007-01-11 | 2008-01-11 | アミノレブリン酸およびその誘導体の使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014094963A true JP2014094963A (ja) | 2014-05-22 |
JP2014094963A5 JP2014094963A5 (ja) | 2014-10-02 |
JP5827702B2 JP5827702B2 (ja) | 2015-12-02 |
Family
ID=37809842
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545231A Expired - Fee Related JP5814508B2 (ja) | 2007-01-11 | 2008-01-11 | アミノレブリン酸およびその誘導体の使用 |
JP2014009382A Active JP5827702B2 (ja) | 2007-01-11 | 2014-01-22 | アミノレブリン酸およびその誘導体の使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009545231A Expired - Fee Related JP5814508B2 (ja) | 2007-01-11 | 2008-01-11 | アミノレブリン酸およびその誘導体の使用 |
Country Status (13)
Country | Link |
---|---|
US (4) | US8759396B2 (ja) |
EP (3) | EP2659888A1 (ja) |
JP (2) | JP5814508B2 (ja) |
KR (2) | KR20090118925A (ja) |
CN (3) | CN101631541A (ja) |
CA (2) | CA2784250C (ja) |
DK (1) | DK2120921T3 (ja) |
ES (2) | ES2546381T3 (ja) |
GB (1) | GB0700580D0 (ja) |
PL (1) | PL2120921T3 (ja) |
PT (1) | PT2120921E (ja) |
SI (1) | SI2120921T1 (ja) |
WO (1) | WO2008084241A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020218577A1 (ja) | 2019-04-26 | 2020-10-29 | ネオファーマジャパン株式会社 | フラビウイルス感染症治療剤 |
WO2022014654A1 (ja) * | 2020-07-15 | 2022-01-20 | ネオファーマジャパン株式会社 | アフリカ豚熱(African Swine Fever:ASF)の治療及び/又は予防剤 |
US11235168B2 (en) | 2015-12-17 | 2022-02-01 | Photocure Asa | Method of photodynamic therapy (PDT) for bladder cancer |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110224598A1 (en) * | 2010-03-12 | 2011-09-15 | Daniel Barolet | Radiant near infrared light emitting diode exposure as skin preparation |
GB0900461D0 (en) | 2009-01-12 | 2009-02-11 | Photocure Asa | Photodynamic therapy device |
PL2440199T3 (pl) * | 2009-06-11 | 2016-10-31 | Półstałe kompozycje i produkty farmaceutyczne | |
US8992954B2 (en) | 2010-03-01 | 2015-03-31 | Photocure Asa | Compositions comprising a derivative of 5-aminolevulinic acid |
US9645154B2 (en) | 2010-12-24 | 2017-05-09 | Arkray, Inc. | Method for detecting cancer cell |
CN102617378B (zh) * | 2011-01-26 | 2016-04-27 | 上海泺安医药技术有限公司 | 一种2-(3’-氨基-2’-氧-丙基)丙二酸酯盐及制备 |
KR101254758B1 (ko) * | 2011-02-28 | 2013-04-15 | 부산대학교병원 | 광역동치료의 광증감제로 사용하기 위한 이디티에이를 이용한 아미노레불리닉산 테트라머 |
KR101254752B1 (ko) * | 2011-02-28 | 2013-04-15 | 부산대학교 산학협력단 | 광역동치료의 광증감제로 사용하기 위한 구연산을 이용한 아미노레불리닉산 트라이머 |
CN102179010B (zh) * | 2011-05-27 | 2013-01-09 | 吉林大学 | 脑胶质瘤光动力直接照射治疗装置 |
RU2615870C2 (ru) * | 2011-12-19 | 2017-04-11 | ФотоКьюэр АСА | Устройство облучения |
JP5883889B2 (ja) * | 2012-01-26 | 2016-03-15 | Sbiファーマ株式会社 | 光線力学的診断剤、及び、フォトブリーチング防止剤 |
US20140067024A1 (en) | 2012-08-30 | 2014-03-06 | Photocure Asa | Dual panel photodynamic therapy lamp |
GB201306369D0 (en) | 2013-04-09 | 2013-05-22 | Photocure As | Irradiation device |
KR20150004092A (ko) * | 2013-07-02 | 2015-01-12 | 제너럴바이오(주) | 칼란코에 추출물이 포함된 항산화 액상 조성물 |
US10716855B2 (en) * | 2013-12-20 | 2020-07-21 | Galderma Research & Development | Pulse photodynamic treatment of photodamaged skin |
PL229756B1 (pl) | 2014-11-12 | 2018-08-31 | Tarchominskie Zaklady Farmaceutyczne Polfa Spólka Akcyjna | Krem do stosowania w diagnostyce i terapii z zastosowaniem metody fotodynamicznej |
CN109939361B (zh) * | 2014-11-19 | 2021-04-06 | 夏普株式会社 | 光动力学治疗装置 |
US10603508B2 (en) | 2015-10-15 | 2020-03-31 | Dusa Pharmaceuticals, Inc. | Adjustable illuminators and methods for photodynamic therapy and diagnosis |
ES2860807T3 (es) | 2015-10-15 | 2021-10-05 | Dusa Pharmaceuticals Inc | Iluminador ajustable para terapia y diagnóstico fotodinámicos |
US10632324B2 (en) | 2017-04-27 | 2020-04-28 | 9127-4910 Quebec Inc. | Method for the treatment of skin tissues |
WO2019018408A1 (en) * | 2017-07-17 | 2019-01-24 | Andrea Willey | METHOD OF PHOTODYNAMIC THERAPY AGAINST SKIN DISORDERS |
US10357567B1 (en) | 2018-01-12 | 2019-07-23 | Dusa Pharmaceuticals, Inc. | Methods for photodynamic therapy |
US11642411B2 (en) * | 2018-08-23 | 2023-05-09 | Biofrontera Bioscience Gmbh | Photodynamic therapy comprising two light exposures at different wavelengths |
AU2020303417A1 (en) | 2019-06-25 | 2022-01-27 | Dusa Pharmaceuticals, Inc. | Methods for reducing pain during photodynamic therapy of actinic keratosis |
CN113620828A (zh) * | 2021-08-17 | 2021-11-09 | 湖南复瑞生物医药技术有限责任公司 | 一种5-氨基酮戊酸酯化物、用途和农药组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004506005A (ja) * | 2000-08-16 | 2004-02-26 | ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル | 尋常性挫瘡用の局所アミノレブリン酸−光力学的治療 |
WO2006051269A1 (en) * | 2004-11-10 | 2006-05-18 | Photocure Asa | Treatment of acne using derivatives of 5-aminolevulinic acid |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5079262A (en) | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
US5234940A (en) | 1989-07-28 | 1993-08-10 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
US5422093A (en) | 1989-07-28 | 1995-06-06 | Queen's University | Photochemotherapeutic method using 5-aminolevulinic acid and precursors thereof |
US5955490A (en) | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
CA2215069C (en) | 1995-03-10 | 2006-09-12 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
GB9700396D0 (en) * | 1997-01-10 | 1997-02-26 | Photocure As | Photochemotherapeutic compositions |
AUPQ044499A0 (en) | 1999-05-19 | 1999-06-10 | Commonwealth Scientific And Industrial Research Organisation | Control of wool growth |
GB0018527D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Composition |
GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
US6723750B2 (en) * | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
AU2003230808A1 (en) | 2002-04-05 | 2003-10-27 | Candela Corporation | High fluence rate activation of photosensitizers for dermatological applications |
US20040048842A1 (en) * | 2002-09-10 | 2004-03-11 | Mcmillan Kathleen | Method of treating skin disorders |
WO2004034889A2 (en) | 2002-10-18 | 2004-04-29 | The Regents Of The University Of California | Photodynamic therapy for ocular neovascularization |
US20050209330A1 (en) | 2004-03-22 | 2005-09-22 | Syneron Medical Ltd. | Method of treatment of skin |
US20050209331A1 (en) | 2004-03-22 | 2005-09-22 | Syneron Medical Ltd. | Method of treatment of skin |
GB0406917D0 (en) * | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
GB0609809D0 (en) * | 2006-05-17 | 2006-06-28 | Photocure Asa | Product |
-
2007
- 2007-01-11 GB GBGB0700580.4A patent/GB0700580D0/en not_active Ceased
-
2008
- 2008-01-11 ES ES08701770.3T patent/ES2546381T3/es active Active
- 2008-01-11 KR KR1020097016703A patent/KR20090118925A/ko not_active Application Discontinuation
- 2008-01-11 DK DK08701770.3T patent/DK2120921T3/en active
- 2008-01-11 EP EP13173602.7A patent/EP2659888A1/en not_active Withdrawn
- 2008-01-11 EP EP14163782.7A patent/EP2754439B1/en active Active
- 2008-01-11 CN CN200880002124A patent/CN101631541A/zh active Pending
- 2008-01-11 JP JP2009545231A patent/JP5814508B2/ja not_active Expired - Fee Related
- 2008-01-11 KR KR1020147014684A patent/KR20140076641A/ko active Search and Examination
- 2008-01-11 PT PT87017703T patent/PT2120921E/pt unknown
- 2008-01-11 US US12/523,048 patent/US8759396B2/en active Active
- 2008-01-11 CN CN201410834714.2A patent/CN104524576A/zh active Pending
- 2008-01-11 EP EP08701770.3A patent/EP2120921B1/en not_active Not-in-force
- 2008-01-11 PL PL08701770T patent/PL2120921T3/pl unknown
- 2008-01-11 SI SI200831500T patent/SI2120921T1/sl unknown
- 2008-01-11 CA CA2784250A patent/CA2784250C/en not_active Expired - Fee Related
- 2008-01-11 WO PCT/GB2008/000086 patent/WO2008084241A2/en active Application Filing
- 2008-01-11 CN CN201410331370.3A patent/CN104069493A/zh active Pending
- 2008-01-11 ES ES14163782T patent/ES2900528T3/es active Active
- 2008-01-11 CA CA2675334A patent/CA2675334C/en active Active
-
2012
- 2012-10-10 US US13/648,946 patent/US20130090592A1/en not_active Abandoned
-
2014
- 2014-01-22 JP JP2014009382A patent/JP5827702B2/ja active Active
-
2015
- 2015-02-06 US US14/616,278 patent/US20150150972A1/en not_active Abandoned
- 2015-10-02 US US14/873,566 patent/US10543272B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004506005A (ja) * | 2000-08-16 | 2004-02-26 | ザ ジェネラル ホスピタル コーポレイション ディー ビー エイ マサチューセッツ ジェネラル ホスピタル | 尋常性挫瘡用の局所アミノレブリン酸−光力学的治療 |
WO2006051269A1 (en) * | 2004-11-10 | 2006-05-18 | Photocure Asa | Treatment of acne using derivatives of 5-aminolevulinic acid |
JP2008519812A (ja) * | 2004-11-10 | 2008-06-12 | フォトキュア エイエスエイ | 5―アミノレブリン酸の誘導体を用いる座瘡の治療方法 |
Non-Patent Citations (7)
Title |
---|
JPN6014039468; ANDREJEVIC-BLANT, S. et al: 'Time-dependent hexaminolaevulinate induced protoporphyrin IX distribution after topical application' Lasers Surg. Med. Vol.35, No.4, 2004, p.276-283 * |
JPN6014039469; WIERRANI, F. et al: '5-aminolevulinic acid-mediated photodynamic therapy of intraepithelial neoplasia and human papilloma' Cancer Detect. Prev. Vol.23, No.4, 1999, p.351-355 * |
JPN6014039470; BABILAS, P. et al: 'In vitro and in vivo comparison of two different light sources for topical photodynamic therapy' Br. J. Dermatol. Vol.154, No.4, 2006, p.712-718 * |
JPN6014039471; WOLF, P. et al: 'Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic ac' J. Am. Acad. Dermatol. Vol.31, No.4, 1994, p.678-680 * |
JPN6014039472; VAN DEN BOOGERT, J. et al: 'Photodynamic therapy for esophageal lesions: selectivity depends on wavelength, power, and light dos' Ann. Thorac. Surg. Vol.68, No.5, 1999, p.1763-1769 * |
JPN6014039473; ROBINSON, D.J. et al: 'Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal h' Photochem. Photobiol. Vol.67, No.1, 1998, p.140-149 * |
JPN6015021267; J. Photochem. Photobiol. B., 2001, Vol.60, No.1, p.37-43 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11235168B2 (en) | 2015-12-17 | 2022-02-01 | Photocure Asa | Method of photodynamic therapy (PDT) for bladder cancer |
WO2020218577A1 (ja) | 2019-04-26 | 2020-10-29 | ネオファーマジャパン株式会社 | フラビウイルス感染症治療剤 |
WO2022014654A1 (ja) * | 2020-07-15 | 2022-01-20 | ネオファーマジャパン株式会社 | アフリカ豚熱(African Swine Fever:ASF)の治療及び/又は予防剤 |
Also Published As
Publication number | Publication date |
---|---|
EP2754439A3 (en) | 2014-10-01 |
CA2675334A1 (en) | 2008-07-17 |
EP2120921B1 (en) | 2015-06-17 |
CA2784250A1 (en) | 2008-07-17 |
CN104069493A (zh) | 2014-10-01 |
US10543272B2 (en) | 2020-01-28 |
KR20140076641A (ko) | 2014-06-20 |
SI2120921T1 (sl) | 2015-10-30 |
JP2010515714A (ja) | 2010-05-13 |
US20160030565A1 (en) | 2016-02-04 |
JP5827702B2 (ja) | 2015-12-02 |
DK2120921T3 (en) | 2015-08-24 |
ES2900528T3 (es) | 2022-03-17 |
CN104524576A (zh) | 2015-04-22 |
PL2120921T3 (pl) | 2015-12-31 |
US20130090592A1 (en) | 2013-04-11 |
WO2008084241A2 (en) | 2008-07-17 |
JP5814508B2 (ja) | 2015-11-17 |
US20150150972A1 (en) | 2015-06-04 |
KR20090118925A (ko) | 2009-11-18 |
CN101631541A (zh) | 2010-01-20 |
ES2546381T3 (es) | 2015-09-23 |
CA2675334C (en) | 2014-02-25 |
WO2008084241A3 (en) | 2008-09-18 |
GB0700580D0 (en) | 2007-02-21 |
PT2120921E (pt) | 2015-09-30 |
EP2659888A1 (en) | 2013-11-06 |
EP2120921A2 (en) | 2009-11-25 |
EP2754439A2 (en) | 2014-07-16 |
US8759396B2 (en) | 2014-06-24 |
CA2784250C (en) | 2016-03-15 |
EP2754439B1 (en) | 2021-10-13 |
US20100137439A1 (en) | 2010-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5827702B2 (ja) | アミノレブリン酸およびその誘導体の使用 | |
US8546447B2 (en) | Treatment of acne using derivatives of 5-aminolevulinic acid | |
JP2005501050A (ja) | 方法 | |
JP6639398B2 (ja) | 座瘡のパルス光力学的処置 | |
WO2013092936A2 (en) | Use of 5-aminolevulinic acid and esters, in combination with a vitamin d derivative or analog in photochemotherapy, and their uses in treating acne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140814 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20140814 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20140827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150602 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150902 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151016 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5827702 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |